Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Circ Heart Fail. 2019 Jun 21;12(7):e006125. doi: 10.1161/CIRCHEARTFAILURE.119.006125

Figure 2: Average Number of Signs of Congestion During Follow-up by Randomization Arm.

Figure 2:

Spironolactone (red) reduced congestion more than placebo (blue) during the majority of follow-up, shown from baseline to the 54-month visit. Subsequent visits were truncated due to small number of individuals in both arms. Error bars denote 95% confidence intervals.